The Pulmonary Arterial Hypertension Market Size was valued at USD 7.5 billion in 2023. The Pulmonary Arterial Hypertension Market industry is projected to grow from USD 7.9 billion in 2024 to USD 11.5 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.60% during the forecast period (2024 - 2032). A rise in the rate of pulmonary hypertension and a robust product pipeline are the primary market drivers propelling the market's expansion.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Prostacyclin and Prostacyclin Analogs fragment is supposed to show better development in the forecast period, attributable to the high deals of these medications and the rising number of medication endorsements. For example, in June 2022, United Therapeutic Corporation announced the US Food and Medication Organization's endorsement of Tyvaso DPI (treprostinil) inward breath powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension related to interstitial lung illness to develop practice capacity further. Tyvaso DPI conveys the demonstrated viability of treprostinil through a little inhaler that fits in the patient's hand, making it one of the least complex ways for patients to regulate a prostacyclin. A rare illness influences less than 200,000 people in the US, as per information from the Genetic and Rare Diseases Information Data Center, which was delivered in January 2021 under the Orphan Drug Act. Different countries may have formal criteria for uncommon illnesses. Less than 1 in 2,000 persons are afflicted by an illness, for example, and it is deemed uncommon by the European Union. Roughly 7,000 rare diseases have been recognized, and one in ten Americans, or roughly 30 million people, suffer from a rare ailment.
Additionally, Pervasiveness and etiologies of pulmonary hypertension (PH) at Somalia-Turkey Preparing and Exploration Clinic in Mogadishu' distributed in December 2021, the prevalence of PH was viewed as 18%, which is a lot higher than that of the typical European nations. Likewise, according to another article named 'The Frequency and Predominance of Pulmonary Hypertension in the COPD Populace: A Deliberate Survey and Meta-Analysis distributed in February 2022, the worldwide occurrence of PH in the Chronic obstructive pulmonary disease (COPD) populace is extremely high, and there are critical provincial and global varieties. Patients with COPD ought to be evaluated for PH and contributing gamble elements to lessen the weight on people and society. Pneumonic hypertension happens at all ages, and its frequency increases with age. The high development is ascribed to evolving ways of life, as far as the absence of active work and expanded utilization of liquor and tobacco, which builds the possibility of creating hypertension and high blood pressure. The expanded blood pressure, thus, brings about different infections, for example, stroke and heart attacks. Hypertension is viewed as a variable well-being risk and is often connected with high morbidity and mortality. In this way, the previously mentioned factors are supposed to drive the market CAGR growth.
Additionally, Governments often collaborate with drug organizations, research establishments, and medical care associations to offer regulatory guidance, administrative direction, and incentives for drug improvement in PAH. Financing drives, for example, awards and appropriations, empower scientists to direct preclinical and clinical preliminaries, working with the investigation of novel treatments and the improvement of existing ones. For instance, in September 2022, Eko got subsidizing of around USD 2.7 million from NIH for the improvement of cutting-edge algorithms and coordinated advancements to manage aspiratory blood vessel hypertension. Thus, this drives the pulmonary arterial hypertension market revenue.
Based on Drug Class, the Pulmonary Arterial Hypertension Market segmentation includes prostacyclin and prostacyclin analogs, SGC stimulators, endothelin receptor antagonists (ERAs), and PDE-5 inhibitors. In 2023, the prostacyclin and prostacyclin analogs segment dominated the market. Prostacyclin is a major area of strength and one of the most outstanding meds for the treatment of PAH. It is made from arachidonic destructive through the Cyclooxygenase (COX) pathway and is conveyed by endothelial cells in aspiratory passage. Prostacyclin binds to the prostaglandin receptors to progress the loosening up of smooth muscles and vasodilation through the enactment of G protein and protein kinase. The oral prostacyclin receptor agonist selexipag has demonstrated encouraging outcomes for the treatment of PAH, according to a survey sent by specialists at the American School of Cardiology in October 2023. At this point, the social occasion is managing to investigate the ampleness of Prostacyclin for pulmonary arterial hypertension.
The SGC stimulators category is anticipated to be the fastest growing. An essential component of the cardiovascular system is soluble guanylate cyclase (SGC). Moreover, it is the nitric oxide (NO) receptor. Cardiopulmonary illnesses like PAH, which is linked to decreased NO production, have made it a viable therapeutic target. Along with insufficient activation of the NO-sGC-cGMP pathway, it also causes endothelial dysfunction. This prevents individuals with PAH from experiencing vasorelaxation and smooth muscle growth.
Figure 1: Pulmonary Arterial Hypertension Market, by Drug Class, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Based on Type, the Pulmonary Arterial Hypertension Market segmentation includes branded and generics. In 2023, the branded category generated the most income. A robust pipeline, a growing number of product approvals, and significant expenditures made by market participants account for the majority of the branded industry. Moreover, an increasing number of product releases is anticipated to support category growth throughout the projection period. For example, United Therapeutics Corporation gained FDA clearance in June 2022 for its Tyvaso DPI powder, which is planned to treat pulmonary arterial hypertension.
The Pulmonary Arterial Hypertension generics segment market is anticipated to grow the fastest during the forecast period. By 2030, variables like price, patent expiration, and accessibility should contribute to the expansion of the generic market. Lupin declared in September 2022 that generic Sildenafil will be available in the United States for the treatment of pulmonary arterial hypertension.
Based on the Route of Administration, the Pulmonary Arterial Hypertension Market segmentation includes oral, intravenous/subcutaneous, and inhalational. The oral category leads the market. Patient preference for the oral method of administration and the increasing availability of oral formulations for PAH are the causes of this. Among the oral PAH medications are Letairis, Opsumit, Adcirca, and Revatio. A positive potential for segment expansion is also anticipated by an increase in the approvals of novel oral formulations throughout the projection period. The FDA approved Tenax Therapeutics, Inc.'s TNX-103 IND application in November 2023, for example. The business is looking into the use of oral levosimendan to treat pulmonary arterial hypertension.
The Pulmonary Arterial Hypertension market’s intravenous/ subcutaneous segment is anticipated to grow fastest during the projection period. IV drugs have been demonstrated to be rather helpful in treating pulmonary arterial hypertension (PAH). These drugs can soon achieve therapeutic concentrations when injected straight into the bloodstream, which relieves symptoms right away. For the purpose of treating the intricate pathophysiology of PAH, intravenous infusion guarantees consistent absorption and bioavailability. Furthermore, allowing precise dosage adjustments improves treatment outcomes.
By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Pulmonary Arterial Hypertension market will dominate this market. Enhanced consciousness, a high diagnostic rate, and encouraging government programs. The Centers for Disease Control and Prevention presented statistics in August 2022 about the Million Hearts national initiative, which aims to prevent one million heart attacks and strokes within five years. By implementing a small number of evidence-based goals and targets, its primary objective is to improve everyone's cardiovascular health.
Another example is the World Health Organization's (WHO) global HEARTS Initiative, which assists nations in bolstering their efforts to prevent cardiovascular disease (CVD). These efforts include improved tobacco control, dietary salt reduction, physical activity promotion, removal of industrially produced dietary trans-fat, and risk management for CVD. Regarding pulmonary arterial hypertension initiatives, some beneficial advancements have been demonstrated by businesses and funded by the government.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: PULMONARY ARTERIAL HYPERTENSION MARKET SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's Pulmonary Arterial Hypertension market accounts for the second-largest market share. The presence of government organizations like the European Drugs Office and the European Medicines Agency (EMA) of Cardiology advancing early and preventive diagnosis of PAH (Pulmonary arterial hypertension) is likely to spur the development of the market from here on out. The elements supporting the European market are the rising occurrence of chronic diseases like HIV, PAH, cardiovascular sicknesses, and others. Further, expanding older populations, changes in lifestyle, immobility in day-to-day everyday practice, and contamination in the climate are going to help the Pulmonary Arterial Hypertension Market. Further, the German Pulmonary Arterial Hypertension market held the largest market share, and the UK Pulmonary Arterial Hypertension market was the fastest-growing market in the European region.
The Asia-Pacific Pulmonary Arterial Hypertension Market is expected to grow at the fastest CAGR from 2024 to 2032. Economic advancements in nations like China and India are anticipated to support market expansion. Due to the high population and low per capita income, the need for accessible treatment choices increased. MNCs prioritize investment in developing nations like China and India. Moreover, China’s Pulmonary Arterial Hypertension market held the largest market share, and the Indian Pulmonary Arterial Hypertension market was the fastest-growing market in the Asia-Pacific region.
Pulmonary Arterial Hypertension Key Market Players & Competitive Insights
The top companies in the field will continue to make significant R&D investments to extend their product lines, which will fuel the market for pulmonary arterial hypertension. Contractual agreements, mergers and acquisitions, increased investments, collaboration with other companies, and the production of new products are examples of significant market developments. To increase their worldwide reach, market players also take part in a variety of strategic initiatives. In order to survive and expand in a more competitive and dynamic market, the Pulmonary Arterial Hypertension industry must offer reasonably priced products and services.
One of the main strategies manufacturers use in the worldwide Pulmonary Arterial Hypertension market is local manufacturing, which expands the market sector and helps customers by lowering operating costs. The field of pulmonary arterial hypertension has produced some of the greatest medical advances in recent years. Major players in the Pulmonary Arterial Hypertension market, including United Therapeutics Corporation, Johnson & Johnson, Viatris Inc., Bayer, Sandoz Inc., Gilead Sciences, Inc., Lupin Pharmaceuticals, Inc., GlaxoSmithKline, Novartis International AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries, Inc., and others, are engaging in research and development activities in an effort to boost market demand.
Novartis AG is a medical organization that focuses on the discovery, improvement, assembly, and promotion of prescription and generic drug items and eye care items. It gives medications for the therapy of cancer growth, cardiovascular illnesses, dermatological circumstances, neurological problems, ophthalmic and respiratory sicknesses, hematologic sicknesses, solid tumors, immune disorders, and diseases, among others. Novartis conducts research in different illness areas through the BioMedical Exploration division. The Beacon of Hope joint effort, launched by Novartis and the Novartis US Foundation, was extended in July 2023. Aiming to promote diversity, equity, inclusion, and trust within the research and development industry, this initiative has been ongoing for ten years and has been addressing health and education inequities. Large cell arteritis, urticaria, hypertension, pulmonary arterial hypertension, and breast cancer research are among the clinical trials that Beacon of Hope will now cover.
United Therapeutics Corp creates and markets imaginative drug items for the treatment of cardiovascular issues, especially pulmonary arterial hypertension and irresistible illnesses. The organization's items comprise prostacyclin analogs, including Remodulin (treprostinil) infusion, Tyvaso (treprostinil) inward breath arrangement, and treprostinil, orenitram. Adcirca (tadalafil) is an inhibitor of phosphodiesterase type 5 (PDE-5), and Unituxin (dinutuximab) is a monoclonal antibody used in oncology, are different items. Its item competitors incorporate monoclonal antibodies (mAbs), glycobiology antiviral specialists, and cell-based treatments. The organization additionally creates designed lungs for transplantation in the preclinical stage. It makes items in its office in Silver Spring, Maryland. The FDA approved Tyvaso® in April 2021, and the company immediately brought it to market to treat PH-ILD, or pulmonary hypertension associated with interstitial lung disease. This was a major statement made by United Therapeutics Corporation. With this finding, patients with PH-ILD now have hope for a better prognosis, and the firm has a strategic potential to expand its market share in pulmonary hypertension.
Key Companies in the Pulmonary Arterial Hypertension market include
Pulmonary Arterial Hypertension Industry Developments
July 2022: The first patient has been recruited in the Phase II research of drug candidate CS1 for pulmonary arterial hypertension (PAH), according to Cereno Scientific.
June 2022: Important preclinical evidence published supports the promise of erlotinib as a therapy for pulmonary arterial hypertension (PAH), according to Gossamer Bio, Inc.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 7.5 Billion |
| Market Size 2024 | USD 7.9 Billion |
| Market Size 2032 | USD 11.5 Billion |
| Compound Annual Growth Rate (CAGR) | 5.60% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019-2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Drug Class, Type, Route of Administration, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | United Therapeutics Corporation, Johnson & Johnson, Viatris Inc., Bayer, Sandoz Inc., Gilead Sciences, Inc., Lupin Pharmaceuticals, Inc., GlaxoSmithKline, Novartis International AG, Teva Pharmaceutical Industries Ltd., and Sun Pharmaceutical Industries, Inc. |
| Key Market Opportunities | · Expanded diagnostic tools and rising adoption of patient-centric care models |
| Key Market Dynamics | · A rise in the rate of pulmonary hypertension and a robust product pipeline |
Frequently Asked Questions (FAQ) :
The Pulmonary Arterial Hypertension Market size was valued at USD 7.5 Billion in 2023.
The global market is projected to grow at a CAGR of 5.60%during the forecast period, 2024-2032.
North America had the largest share of the global market
The key players in the market are United Therapeutics Corporation, Johnson & Johnson, Viatris Inc., Bayer, Sandoz Inc., Gilead Sciences, Inc., Lupin Pharmaceuticals, Inc., GlaxoSmithKline, Novartis International AG, Teva Pharmaceutical Industries Ltd., and Sun Pharmaceutical Industries, Inc.
The Prostacyclin and Prostacyclin Analogs category dominated the market in 2023.
Branded category had the largest share in the global market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
